These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17692777)

  • 21. [Short course antibiotherapies in community-acquired pneumonia].
    Bulbul Y; Ozlu T
    Tuberk Toraks; 2008; 56(3):344-52. PubMed ID: 18932039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Initial treatment can lighten low-severity community-acquired pneumonia].
    Wasielewski S
    Med Monatsschr Pharm; 2005 Nov; 28(11):413. PubMed ID: 16309029
    [No Abstract]   [Full Text] [Related]  

  • 23. Community acquired pneumonia.
    Sargeant P
    Aust Fam Physician; 2004 Aug; 33(8):583; author reply 583. PubMed ID: 15373373
    [No Abstract]   [Full Text] [Related]  

  • 24. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of emergency department crowding on time to antibiotics in patients admitted with community-acquired pneumonia.
    Fee C; Weber EJ; Maak CA; Bacchetti P
    Ann Emerg Med; 2007 Nov; 50(5):501-9, 509.e1. PubMed ID: 17913300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
    Bhavnani SM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tsukamurella infection: a rare cause of community-acquired pneumonia.
    Mehta YB; Goswami R; Bhanot N; Mehta Z; Simonelli P
    Am J Med Sci; 2011 Jun; 341(6):500-3. PubMed ID: 21613935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The United States guidelines for the management of community-acquired pneumonia and their relevance to Australasia.
    Waterer GW; Grayson ML
    Intern Med J; 2007 Dec; 37(12):789-91. PubMed ID: 18028080
    [No Abstract]   [Full Text] [Related]  

  • 29. Healthcare-associated pneumonia in the emergency department.
    Slaven EM; Santanilla JI; DeBlieux PM
    Semin Respir Crit Care Med; 2009 Feb; 30(1):46-51. PubMed ID: 19199186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
    Blondeau JM; Tillotson G
    Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
    Tillotson GS; Echols RM
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of emergency department crowding measures on time to antibiotics for patients with community-acquired pneumonia.
    Pines JM; Localio AR; Hollander JE; Baxt WG; Lee H; Phillips C; Metlay JP
    Ann Emerg Med; 2007 Nov; 50(5):510-6. PubMed ID: 17913298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.
    Li JZ; Winston LG; Moore DH; Bent S
    Am J Med; 2007 Sep; 120(9):783-90. PubMed ID: 17765048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
    Long R; Chong H; Hoeppner V; Shanmuganathan H; Kowalewska-Grochowska K; Shandro C; Manfreda J; Senthilselvan A; Elzainy A; Marrie T
    Clin Infect Dis; 2009 May; 48(10):1354-60. PubMed ID: 19348594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Indications for use of fluoroquinolones in the treatment of community acquired pneumonia].
    Mensa J; Martínez JA; Sánchez F; Marcos MA
    Enferm Infecc Microbiol Clin; 1998 Dec; 16 Suppl 2():31-5; discussion 47-52. PubMed ID: 10344096
    [No Abstract]   [Full Text] [Related]  

  • 37. Identifying failure of empirical treatment for pneumonia: vigilance and common sense.
    Lim WS
    Thorax; 2004 Nov; 59(11):918-9. PubMed ID: 15516461
    [No Abstract]   [Full Text] [Related]  

  • 38. Drugs for pneumonia.
    Treat Guidel Med Lett; 2003 Sep; 1(13):83-8. PubMed ID: 15529096
    [No Abstract]   [Full Text] [Related]  

  • 39. Antimicrobial drug prescribing for pneumonia in ambulatory care.
    MacDougall C; Guglielmo BJ; Maselli J; Gonzales R
    Emerg Infect Dis; 2005 Mar; 11(3):380-4. PubMed ID: 15757551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of community-acquired pneumonia.
    Low DE
    CMAJ; 2008 Dec; 179(12):1245-6. PubMed ID: 19047598
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.